A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
Egyptian Journal of Medical Research
The goal of this study is To assess the importance of adding adjuvant TRASTUZUMAB as a standard in her2 over expressed breast cancer. Fifty female patients have known to be HER2 over expressed breast cancer, recruited from clinical oncology clinic at Beni-Suef University hospital and from the insurance hospital at Beni-Suef city. This is retrospective study. This study was done within a six months. The results of this trial indicate that one year of adjuvant trastuzumab should be considered adoi:10.21608/ejmr.2020.89043 fatcat:vudkay5mpbfn3au5geslq5h7bm